Business
Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium
Company reports initial ONA-XR data from the ongoing Phase 2 SMILE trial for metastatic breast cancer will be presented PHILADELPHIA, Nov. 21, 2022 (GLOBE
About this update from Context Therapeutics Inc.
[{"type":"text","content":"Company reports initial ONA-XR data from the ongoing Phase 2 SMILE trial for metastatic breast cancer will be presented\nPHILADELPHIA, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, today announced clinical data on onapristone extended release (ONA-XR) will be presented at the 2022 San Antonio Breast Cancer Symposium® (SABCS®) taking place in San Antonio, Texas, from December 6-10, 2022. “We are pleased that ONA-XR will be featured at SABCS. Initial clinical data from the SMILE trial will be presented, which is being conducted in collaboration with the Wisconsin Oncology Network, as well as a presentation providing an early look at the ELONA trial design that we recently initiated as part of our collaboration agreement with The Menarini Group. We’re excited to reconnect with the oncology community at SABCS, to further highlight the potential of ONA-XR to help improve the lives of people living with breast cancer, and to work toward creating new standards of care in the women’s oncology field that will make a meaningful impact,” said Martin Lehr, CEO of Context Therapeutics. Details on the presentations are as follows: Poster Title: The SMILE Study: A phase II trial of onapristone in combination with fulvestrant for patients with ER-positive and HER2-negative metastatic breast cancer after progression on endocrine therapy and CDK 4/6 inhibitorsPoster ID: OT2-01-02Abstract: 1300819 Session: Ongoing Trials Poster Session 2Date: Wednesday December 7, 2022Time: 5:00 PM - 6:15 PM CTPresenters: Sailaja Kamaraju, M.D., Medical College of Wisconsin, Milwaukee, Wis., and Kari Wisinski, M.D., University of Wisconsin - Madison Poster Title: ELONA: An open-label, phase 1b-2 study of elacestrant, in combination with onapristone in patients with estrogen receptor-positive, progesterone receptor-positive, HER2-negative advanced or metastatic breast cancerPoster ID: OT2-01-04Abstract: 1307318Session: Ongoing Trials Poster Session 2Date: Wednesday December 7, 2022Time: 5:00 PM - 6:15 PM CTPresenter: Erika Hamilton, M.D., Sarah Cannon Research Institute Details on the presentations listed above are also available on the 2022 SABCS website: https://www.sabcs.org/2022-Symposium-Overview About ONA-XRONA-...